That's pretty easy.
Company were forecasting BLA in H1 2023.
That is based on the 6 month approval timeline post submission ( Provided by priority review status )
So they submit by Dec 31st, and they will get a PDUFA date before June 30th, ie commercialization H1 2023.
That is based on the last company announcement in November - after they released the long term survival data.
Or in other words.... prior to 12 days time.
I think share holders will not be updated until FDA have confirmed / accepted the resubmission.
GVHD the first step, page-65
-
- There are more pages in this discussion • 175 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
97.0¢ |
Change
-0.005(0.51%) |
Mkt cap ! $1.113B | |||
| Open | High | Low | Value | Volume |
| 98.5¢ | 98.5¢ | 96.5¢ | $978.2K | 1.002M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 17 | 28519 | 97.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 97.5¢ | 59829 | 63 |
View Market Depth
| Last trade - 13.25pm 23/08/2024 (20 minute delay) ? |
| MSB (ASX) Chart |